| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Over the past several years, some studies have been made on relationship between GVHD and IL-21 by using experimental mouse GVHD model. From these animal studies, blocking the IL-21 signaling after bone marrow transplantation can attenuate GVHD without compromising the GVL effect. IL-21 signal blockade may be an ideal therapeutic target molecule to treat GVHD. Near future, when anti-human IL-21 neutralizing antibody that can be administered to human are developed, they can be used as antibody drugs like tocilizumab and infliximab already used for the treatment of rheumatoid arthritis.
|
